Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical receives Japanese patent for intralymphatic administration of diabetes vaccine Diamyd","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Diamyd Medical AB"},{"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical Reports that Clinical Trial with Remygen[\u00ae] is Expanded to Evaluate Prevention of Hypoglycaemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Diamyd Medical AB"}]

Diamyd Medical AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Diamyd Medical Reports that Clinical Trial with Remygen[®] is Expanded to Evaluate Prevention of Hypoglycaemia

Details:

The Swedish Medical Products Agency has approved an amendment to ReGenerate-1 to investigate Remygen®'s preventive effects on hypoglycaemia (severely reduced blood sugar level) in individuals with long-term type 1 diabetes.

Lead Product(s): Gamma-Aminobutyric Acid,Alprazolam

Therapeutic Area: Endocrinology Product Name: Remygen

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 24, 2020

ASK
US

Upload
your Pipeline Activity

Diamyd Medical AB

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Diamyd Medical receives Japanese patent for intralymphatic administration of diabetes vaccine Diamyd

Details:

The patents protect the administration method of Diamyd® that is now being evaluated in the Phase IIb trial DIAGNODE-2, which previously showed positive results in the Phase I/II trial DIAGNODE-1.

Lead Product(s): rhGAD65

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY